Picture of 4D Molecular Therapeutics logo

FDMT 4D Molecular Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

Momentum

Relative Strength (%)
1m+11.37%
3m+64.37%
6m+76.25%
1yr+31.36%
Volume Change (%)
10d/3m+0.34%
Price vs... (%)
52w High-11.52%
50d MA+29.62%
200d MA+76.59%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-35.17%
Return on Equity-37.4%
Operating Margin-544.65%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of 4D Molecular Therapeutics EPS forecast chart

Profile Summary

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
March 11th, 2015
Public Since
December 11th, 2020
No. of Shareholders
13
No. of Employees
147
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
49,778,127

FDMT Share Price Performance

Upcoming Events for FDMT

Q1 2024 4D Molecular Therapeutics Inc Earnings Release

4D Molecular Therapeutics Inc Annual Shareholders Meeting

Q2 2024 4D Molecular Therapeutics Inc Earnings Release

Similar to FDMT

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Acelyrin logo

Acelyrin

us flag iconNASDAQ Global Select Market

FAQ